174 related articles for article (PubMed ID: 9299577)
21. Molecular biology of prostate cancer.
Isaacs WB; Bova GS; Morton RA; Bussemakers MJ; Brooks JD; Ewing CM
Semin Oncol; 1994 Oct; 21(5):514-21. PubMed ID: 7939745
[TBL] [Abstract][Full Text] [Related]
22. DNA microarray analysis reveals metastasis-associated genes in rat prostate cancer cell lines.
Reyes I; Tiwari R; Geliebter J; Reyes N
Biomedica; 2007 Jun; 27(2):190-203. PubMed ID: 17713630
[TBL] [Abstract][Full Text] [Related]
23. Loss of heterozygosity of the putative prostate cancer susceptibility gene HPC2/ELAC2 is uncommon in sporadic and familial prostate cancer.
Wu YQ; Chen H; Rubin MA; Wojno KJ; Cooney KA
Cancer Res; 2001 Dec; 61(24):8651-3. PubMed ID: 11751379
[TBL] [Abstract][Full Text] [Related]
24. Genetic alterations in human prostate cancer: a review of current literature.
Ozen M; Pathak S
Anticancer Res; 2000; 20(3B):1905-12. PubMed ID: 10928125
[TBL] [Abstract][Full Text] [Related]
25. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer.
Cairns P; Okami K; Halachmi S; Halachmi N; Esteller M; Herman JG; Jen J; Isaacs WB; Bova GS; Sidransky D
Cancer Res; 1997 Nov; 57(22):4997-5000. PubMed ID: 9371490
[TBL] [Abstract][Full Text] [Related]
26. Loss of heterozygosity (LOH), malignancy grade and clonality in microdissected prostate cancer.
Hügel A; Wernert N
Br J Cancer; 1999 Feb; 79(3-4):551-7. PubMed ID: 10027329
[TBL] [Abstract][Full Text] [Related]
27. Molecular biology of prostate cancer.
Karayi MK; Markham AF
Prostate Cancer Prostatic Dis; 2004; 7(1):6-20. PubMed ID: 14999233
[TBL] [Abstract][Full Text] [Related]
28. Loss of heterozygosity at 7q31.1 and 12p13-12 in advanced prostate cancer.
Kawana Y; Ichikawa T; Suzuki H; Ueda T; Komiya A; Ichikawa Y; Furuya Y; Akakura K; Igarashi T; Ito H
Prostate; 2002 Sep; 53(1):60-4. PubMed ID: 12210480
[TBL] [Abstract][Full Text] [Related]
29. An 800-kb region of deletion at 13q14 in human prostate and other carcinomas.
Chen C; Frierson HF; Haggerty PF; Theodorescu D; Gregory CW; Dong JT
Genomics; 2001 Oct; 77(3):135-44. PubMed ID: 11597138
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.
Tamboli P; Amin MB; Xu HJ; Linden MD
Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470
[TBL] [Abstract][Full Text] [Related]
31. The MXI1 tumor suppressor gene is not mutated in primary prostate cancer.
Kuczyk MA; Serth J; Bokemeyer C; Schwede J; Herrmann R; Machtens S; Grünewald V; Höfner K; Jonas U
Oncol Rep; 1998; 5(1):213-6. PubMed ID: 9458379
[TBL] [Abstract][Full Text] [Related]
32. Genetic and microenvironmental implications in prostate cancer progression and metastasis.
Alberti C
Eur Rev Med Pharmacol Sci; 2008; 12(3):167-75. PubMed ID: 18700688
[TBL] [Abstract][Full Text] [Related]
33. Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors.
Calvo A; Xiao N; Kang J; Best CJ; Leiva I; Emmert-Buck MR; Jorcyk C; Green JE
Cancer Res; 2002 Sep; 62(18):5325-35. PubMed ID: 12235003
[TBL] [Abstract][Full Text] [Related]
34. [Recent advances on molecular pathology of prostate carcinoma].
Niu HL; Tao Y
Ai Zheng; 2003 May; 22(5):552-6. PubMed ID: 12753724
[TBL] [Abstract][Full Text] [Related]
35. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer.
Turley RS; Finger EC; Hempel N; How T; Fields TA; Blobe GC
Cancer Res; 2007 Feb; 67(3):1090-8. PubMed ID: 17283142
[TBL] [Abstract][Full Text] [Related]
36. [Research on functional localization and cloning of metastasis suppressor genes].
Liu H; Ye SL
Ai Zheng; 2003 Nov; 22(11):1237-40. PubMed ID: 14613661
[TBL] [Abstract][Full Text] [Related]
37. Identification of a I-cM region of common deletion on 13q14 associated with human prostate cancer.
Ueda T; Emi M; Suzuki H; Komiya A; Akakura K; Ichikawa T; Watanabe M; Shiraishi T; Masai M; Igarashi T; Ito H
Genes Chromosomes Cancer; 1999 Mar; 24(3):183-90. PubMed ID: 10451697
[TBL] [Abstract][Full Text] [Related]
38. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
Dobosy JR; Roberts JL; Fu VX; Jarrard DF
J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
[TBL] [Abstract][Full Text] [Related]
39. [Molecular pathology of prostate carcinoma. Academic playground or guide for diagnosis and therapy planning?].
Bubendorf L
Verh Dtsch Ges Pathol; 2004; 88():158-64. PubMed ID: 16892547
[TBL] [Abstract][Full Text] [Related]
40. Chromosome 17-mediated dormancy of AT6.1 prostate cancer micrometastases.
Chekmareva MA; Kadkhodaian MM; Hollowell CM; Kim H; Yoshida BA; Luu HH; Stadler WM; Rinker-Schaeffer CW
Cancer Res; 1998 Nov; 58(21):4963-9. PubMed ID: 9810006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
